BGB-A1217 is a humanized, IgG1 monoclonal antibody against TIGIT. Tislelizumab is a humanized, IgG4-variant monoclonal antibody against PD-1. This study tests the safety and anti-tumor effect of BGB-A1217 in combination with tislelizumab in patients with advanced solid tumors.
Study of BGB-A1217 in Combination With Tislelizumab in Advanced Solid Tumors
Sponsor / Cooperative group:
Trial & Patient Characteristics
18 years and older
Locally Recurrent or Locally Advanced; Metastatic or Widespread